An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of cediranib in combination
with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or
epithelial cancer, after first line platinum based treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Medical Research Council
Collaborators:
ANZGOG AstraZeneca Australia New Zealand Gynaecological Oncology Group Cancer Research UK Grupo Español de Investigación en Cáncer de Ovario National Health and Medical Research Council, Australia NCIC Clinical Trials Group